ArticleNature communications2018
SIRT6 haploinsufficiency induces BRAF
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 99 citations in OpenAlex.
- A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma.Cancer discovery · 2026Article
- Article
- miR-130b-5p Regulates Expression of ERβ via IGFBP2/SREBP1 Axis in Human Endometriotic Stromal Cells.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- From modification to malignancy: Bridging acetylation mechanisms and therapeutic innovations in melanoma (Review).Oncology reports · 2026Review
- SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target.Cell death & disease · 2025Article
- Pharmacological activation of SIRT6 suppresses progression of head and neck and esophageal squamous cell carcinoma by modulation of cellular metabolism and protein translation.Cell death & disease · 2025Article
- Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis.Cancer research communications · 2024Article
- ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma.Cell reports · 2024Article
- H2A.Z chaperones converge on E2F target genes for melanoma cell proliferation.Genes & development · 2024Article
- Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes.Nature chemical biology · 2024Article
- The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.The Journal of clinical investigation · 2024Article
- SIRT6 promotes metastasis and relapse in HER2-positive breast cancer.Scientific reports · 2023Article
- Functional analysis of recurrent CDC20 promoter variants in human melanoma.Communications biology · 2023Article
- H2A.Z chaperones converge on histone H4 acetylation for melanoma cell proliferation.bioRxiv : the preprint server for biology · 2023Article
- BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.Cancers · 2023Review
- The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer.Apoptosis : an international journal on programmed cell death · 2022Article
- Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.Cancers · 2022Review
- BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Current treatment options in oncology · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Thomas StrubDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Flavia G GhiraldiniDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Saul CarcamoDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Man LiCutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Aleksandra WroblewskaDepartment of Genetics and Genomic Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Rajendra SinghDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Matthew S GoldbergDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Dan HassonDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Zichen WangDepartment of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0002-1415-1286
Stuart J GallagherCentenary Institute, Camperdown NSW 2050, The University of Sydney, Sydney, Australia.
Peter HerseyCentenary Institute, Camperdown NSW 2050, The University of Sydney, Sydney, Australia.
Avi Ma'ayanDepartment of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.ORCID http://orcid.org/0000-0002-6904-1017
Georgina V LongMelanoma Institute Australia, Wollstonecraft NSW 2065, The University of Sydney, Sydney, Australia.
Richard A ScolyerMelanoma Institute Australia, Wollstonecraft NSW 2065, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Brian BrownGraduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Bin ZhengCentenary Institute, Camperdown NSW 2050, The University of Sydney, Sydney, Australia.
Emily BernsteinDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. emily.bernstein@mssm.edu.
Icahn School of Medicine at Mount Sinai · USThe University of Sydney · AUHarvard University · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MData Coordination and Integration Center for LINCS-BD2KU54HL127624 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MA'AYAN, AVI, SCHURER, STEPHAN C · 2014 to 2019
$23.5MPost-transcriptional regulation of the Dendritic Cell transcriptomeR01AI104848 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2013 to 2017
$2.3MTransforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9MTargeting the LKB1-AMPK PATHWAY in Melanoma: Mechanism and Preclinical EvaluationR01CA166717 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ZHENG, BIN · 2012 to 2018
$1.7MSensor-seq: A genome-wide biological measure of microRNA activity.R33CA182377 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, SACHIDANANDAM, RAVI · 2013 to 2015
$1.0MNCI NIH HHS P30 CA196521NCI NIH HHS R01 CA166717NCI NIH HHS R33 CA182377NHLBI NIH HHS U54 HL127624NIAID NIH HHS R01 AI104848NIH HHS S10 OD018522U.S. Department of Defense (DOD) W81XWH-14-1-0230
Abstract
While multiple mechanisms of BRAF
Indexed as
AnimalsApoptosisCell LineCell ProliferationChromatin ImmunoprecipitationDNA DamageFemaleHaploinsufficiencyHumansMelanomaMice, NudeProtein Kinase InhibitorsProto-Oncogene Proteins B-rafReceptor, IGF Type 1Signal TransductionSirtuinsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafReceptor, IGF Type 1SIRT6 protein, humanSirtuins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.